Brain Matters (Audio)

There are modifiable behaviors that may reduce the risk factor of Alzheimer's: vascular disease, sedentary lifestyle, depression/stress, diet factors and alcohol. Kaitlin Casaletto talks about the benefits of an active lifestyle and proper nutrition. Then Dr. Joanna Hellmuth looks at how to decode direct-to-consumer interventions - dietary supplements - and the rise of pseudo-medicine for dementia...

Dr. Julio Rojas-Martinez discusses the pharmacological treatment of Alzheimer’s disease now and what is in development. Current approaches pursue early intervention in the dementia phase. Novel emerging strategies will likely accompany anti-amyloid and anti-tau approaches in the future. Then Sarah Dulaney, RN, describe dementia education, support, and non-pharmacological treatment strategies. Seri...

Alzheimer’s disease is the most common but not the only cause of dementia throughout the lifespan. Dr. Salvatore Spina discusses frontotemporal dementias and how they differ. Series: "Osher WISE: Well-being and Integrative Science for Everyone" [Health and Medicine] [Show ID: 34776]

Dr. Georges Naasan explores the principal clinical syndromes of Alzheimer's Disease: memory, visual, language and frontal/executive. He also discusses neuropathology, genetic factors and modern biomarkers with colleagues from the UCSF Memory and Aging Center. Series: "Osher WISE: Well-being and Integrative Science for Everyone" [Health and Medicine] [Show ID: 34775]

Neurologist Dr. Serggio Lanata explores the neurodegenerative disease of the brain, what they have in common and how they differ. alzheimer's is the most common neurodegenerative disease but there are several others including Parkinson's, Huntington Disease and others. Series: "Osher WISE: Well-being and Integrative Science for Everyone" [Health and Medicine] [Show ID: 34774]

More than 5 million Americans are currently diagnosed with Alzheimer’s disease, and that number is expected to triple by 2050, without prevention or cure. By 2060, the number of Latinos in the United States living with Alzheimer’s disease is projected to increase 832 percent — from 379,000 in 2012, to more than 3.5 million. Find out what UC San Diego is doing to both serve this community and catal...

Alex Figueroa and Dr. Jose Soria-Lopez discuss clinical symptoms of Alzheimer's Disease and the need to include the Latino community in clinical research. Series: "Brain Channel" [Health and Medicine] [Science] [Show ID: 34416]

Rudolph Tanzi, PhD, of the Harvard Medical School describes a fundamental problem with modern-day treatment of Alzheimer's disease. Series: "Wellbeing " [Health and Medicine] [Show ID: 34243]

Dale Bredesen, MD, UCSF and UCLA, discusses how environmental toxins may lead to Alzheimers disease. Series: "UCSF Consortium for Obesity Assessment, Study and Treatment" [Health and Medicine] [Education] [Professional Medical Education] [Show ID: 34090]

There are different types of genetic influences on people's risk of developing Alzheimer's disease. Douglas Galasko, MD, of the UCSD Shiley-Marcos Alzheimer’s Disease Research Center joins William Mobley, MD, PhD to discuss these genes, how they are being studied, and what being a carrier of Alzheimer's associated genes means. Learn more about penetrance and expressivity, genome-wide association s...

How do you model a disease process that stretches out over 20 years in a way that helps you intervene in that process? In the inaugural Shiley Endowed Lecture, Bradley Hyman, MD, PhD shares his research on the progression of Alzheimer's disease. Series: "Brain Channel" [Health and Medicine] [Science] [Show ID: 33992]

Jennifer A. Dresen, MSW, MPH. Chief of Health and Housing Services, The Arc San Francisco Series: "Developmental Disabilities Update" [Health and Medicine] [Education] [Professional Medical Education] [Show ID: 33522]

Michael Rafii, MD, PhD describes the conditions that affect people with Down syndrome including vision issues, hearing issues, hormonal issue, spinal cord issues, sleep apnea, and Alzheimer's disease. He stresses the need for routine medical follow ups with primary care physicians and specialty clinics to make sure all changes in health are addressed. Series: "Brain Channel" [Health and Medicine]...

Karen Gaffney, advocate and disability champion, discusses her life with Down syndrome. She also talks about the impact that pre natal testing is having on the Down syndrome community and advocates for medical research to focus on the immediate needs such as Alzheimer's disease prevention. Series: "Brain Channel" [Health and Medicine] [Science] [Show ID: 33602]

William Mobley, MD, PhD shares the latest research on preventing Alzheimer's disease in people with Down syndrome. He looks at the genetics and progression of both conditions and shares potential therapies to reduce APP expression that leads to dementia. Series: "Alzheimer’s Disease" [Health and Medicine] [Science] [Show ID: 33600]

Can (Martin) Zhang of Harvard Medical School leads off the panel with a detailed discussion of factors leading to Alzheimer’s disease and the potential benefits of curcumin in treatment. He is followed by Rinchen Dhondrup of Qinghai University, who presents on treating chronic atrophic gastritis and Chenchen Wang of Tufts University who explains her work using Tibetan medicines and Tai Chi to trea...

Keynote talks at the 2017 Tibetan Medicine Conference on Mind-Body Health are presented here, including Rudolph Tanzi, PhD, of the Harvard Medical School who describes his research with natural products to prevent and treat Alzheimer's; Yumba of Lhasa on the Great Treasury of Tibetan Medical and Astronomical Texts; and Janet Gyatso of the Harvard Divinity School on the Challenges for the Study of...

Can we turn off the genes responsible for neurodegenerative diseases? Designer DNA drugs are making this possible. By identifying and targeting the genes that drive disease, scientists are moving closer to treatments for ALS, Huntington's disease, and more. Don W. Cleveland, PhD, Department of Cellular and Molecular Medicine, UC San Diego joins William Mobley, MD, PhD to talk about how these drugs...

Igor Grant, MD, FRCP(C) pursues research that addresses real world behavioral problems. Studying the intersection of drugs of abuse (primarily methamphetamine) and infection, his work sheds light on the basic mechanisms of injury for people with HIV. He examines inflammation in the context of neurological disorders and measures the impact of chronic stress on Alzheimer's disease caregivers. Dr. Gr...

2016 Kavli Prize recipient Carla Shatz from Stanford University presents a lively exploration of how understanding early stages of neural development may be leading to a pathway for developing treatments for Alzheimer's Disease. Series: "Alzheimer’s Disease" [Health and Medicine] [Science] [Show ID: 31763]

Eric Siemers, MD, Distinguished Medical Fellow at Eli Lilly and Company joins William Mobley, MD, PhD to discuss clinical trails for Alzheimer's disease. He explains the trial design, results, and future implications of the EXPEDITION3 trial for people with with mild dementia due to Alzheimer's disease. Learn more about potential treatments in the clinical trials pipeline that may impact both the...

As baby boomers age, an unprecedented number of people will be diagnosed with Alzheimer's disease. The economic and social impacts will be wide reaching from cost of treatment to the effect on caregivers. Maria Carrillo, PhD, Chief Science Officer, Alzheimer’s Association joins Willliam Mobley. MD, PhD to discuss what can be done and how government, industry and the Alzheimer's Association are wor...

Ara Khachaturian, PhD, chair and president of the National Biomedical Research Ethics Council joins WIilliam Mobley, MD, PhD to discuss the evolution of biomedical research in Alzheimer's disease and the ethical standards needed to maintain excellent patient care. From institutional review boards (IRB) to industry and academic partnerships, learn how we can support and maintain effective research...

Phyllis Ferrell, Vice President and Global Development Leader for Alzheimer's Disease at Eli Lilly and Company joins William Mobley, MD, PhD to talk about the goal set forth in the National Plan to Address Alzheimer’s Disease to “prevent and effectively treat Alzheimer’s disease by 2025.” Ferrell's shares her work to make Alzheimer's dementia preventable by finding ways to slow disease progression...

From neuropathology to molecular target to clinical treatments, where are we on the road to finding an effective treatment for Alzheimer's disease? Howard Feldman, MD, FRCP(C), a neurologist noted for his original research in geriatric cognitive disorders and expertise in large-scale clinical trials, walks through the latest research and shares some tips on brain health. Series: "Stein Institute f...